In animal models of nonalcoholic fatty liver disease, we found that GLP-1 receptor agonists protected the livers of mice with nonalcoholic fatty liver disease by enhancing the liver autophagy/mitophagy pathway, reducing oxidative stress damage, and inhibiting NLRP3 inflammasomes (Yu et al., 2019). This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.